KRW
APLS

Kaufman Rossin Wealth’s Apellis Pharmaceuticals APLS Stock Holding History

Kaufman Rossin Wealth’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,577
Closed -$209K – 144
2025
Q1 		$209K Buy
+9,577
New +$265K 0.15% 135

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kaufman Rossin Wealth's APLS Position: Q2 2025 in Review

Kaufman Rossin Wealth sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 9,577 shares — an estimated $209K sold.

Kaufman Rossin Wealth first reported a position in APLS in Q1 2025 and held it in 1 quarter. The position peaked at $209K in Q1 2025. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • Kaufman Rossin Wealth reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Kaufman Rossin Wealth sold 9,577 Apellis Pharmaceuticals shares in Q2 2025, an estimated $209K.
  • Kaufman Rossin Wealth first reported a position in Apellis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Kaufman Rossin Wealth's Apellis Pharmaceuticals position peaked at $209K in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on Kaufman Rossin Wealth's 13F filing for Q2 2025, filed 11 Jul 2025.